Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery.

Abstract

Window-of-opportunity trials, during which patients receive short-duration pre-surgical therapies, provide a platform for understanding the therapies’ mechanisms of action, but will require a paradigm shift in trial design, specimen collection and analysis.

• Authors: Thomas U Marron, Matthew D Galsky, Bachir Taouli, Maria Isabel Fiel, Stephen Ward, Edward Kim, David Yankelevitz, Deborah Doroshow, Emma Guttman-Yassky, Benjamin Ungar, Saurabh Mehandru, Benjamin J Golas, Daniel Labow, John Sfakianos, Sujit S Nair, Dimple Chakravarty, Michael Buckstein, Xiaoyu Song, Effi Kenigsberg, Sacha Gnjatic, Brian D Brown, Joseph Sparano, Ashutosh Tewari, Myron Schwartz, Nina Bhardwaj, Miriam Merad
• Journal: Nature medicine (Nat Med) Vol. 28 Issue 4 Pg. 626-629 (Apr 2022) ISSN: 1546-170X [Electronic] United States
• PMID: 35347282 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents

Topics

• Antineoplastic Agents (therapeutic use)
• Breast Neoplasms (drug therapy)
• Clinical Trials as Topic
• Drug Discovery
• Female
• Humans
• Neoadjuvant Therapy
• Neoplasms (drug therapy)